Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug weaken or protect aging muscles?

NCT ID NCT07788378

Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks at whether metformin, a common diabetes drug, is linked to muscle strength, muscle mass, and physical function in people aged 60 and older with type 2 diabetes. Researchers will compare older adults who have taken metformin for at least three months to those on other diabetes medications. The goal is to understand if metformin helps or harms muscle health, which is important because muscle loss (sarcopenia) is common and serious in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin
What this could lead to
If metformin is linked to better muscle health, it could guide safer diabetes treatment choices for older adults, potentially reducing frailty and fall risk.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Previous research has been mixed, with some studies suggesting metformin might even impair muscle function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

290 people

The number who actually took part.

Started

Nov 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Elderly patients with type 2 diabetes hospitalized at the Department of Endocrinology, Huadong Hospital affiliated to Fudan University, from August 1, 2018, to August 31, 2023, were enrolled. Inclusion criteria: (1) age ≥ 60 years; (2) diagnosed with type 2 diabetes; (3) stable glucose-lowering regimen for at least three months prior to admission; (4) completed Bioelectrical Impedance Analysis (BIA), grip strength, and gait speed assessments;(5) The reason for hospitalization was to regulate blood glucose. Exclusion criteria: (1) diabetic ketoacidosis or hyperosmolar coma; (2) severe hepatic, renal, or cardiopulmonary dysfunction, or severe gastrointestinal disease; (3) active malignant tumors; (4) use of glucocorticoids or antipsychotic drugs; (5) active infectious diseases; (6) severe musculoskeletal diseases.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥ 60 years; * diagnosed with type 2 diabetes; * stable glucose-lowering regimen for at least three months prior to admission; * completed Bioelectrical Impedance Analysis (BIA), grip strength, and gait speed assessments; * The reason for hospitalization was to regulate blood glucose; Exclusion Criteria: * diabetic ketoacidosis or hyperosmolar coma; * severe hepatic, renal, or cardiopulmonary dysfunction, or severe gastrointestinal disease; * active malignant tumors; * use of glucocorticoids or antipsychotic drugs; * active infectious diseases; * severe musculoskeletal diseases;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete type 2 Metformin Muscle mass Muscle strength Physical function

Contacts and locations

Locations

  • Huadong Hospital, Fudan University

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.